Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066417 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00066417 is a Phase 2 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 51 participants.
The verdict
NCT00066417, a Phase 2 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in treating patients with high-risk leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG methylprednisolone
- DRUG fludarabine phosphate
- DRUG cyclosporine
- DRUG therapeutic allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066417
The ClinicalTrials.gov registry entry for NCT00066417 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00066417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066417 about?
NCT00066417 is a clinical study titled "Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia". RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly ...
What is the current status of trial NCT00066417?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 51 participants. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00066417?
The interventions under investigation include: cyclophosphamide (DRUG), methylprednisolone (DRUG), fludarabine phosphate (DRUG), cyclosporine (DRUG), therapeutic allogeneic lymphocytes (DRUG).
Who is sponsoring clinical trial NCT00066417?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.